TIDMCOG

RNS Number : 2437H

Cambridge Cognition Holdings PLC

14 November 2018

Cambridge Cognition Holdings Plc

('Cambridge Cognition' or the 'Company')

Contract win in growing eCOA revenue stream

Cambridge Cognition Holdings plc (AIM: COG), which develops and markets neuroscience technology to assess brain health, today announced it has won a significant new clinical trial contract, which is the largest in a series of recently signed electronic clinical outcomes assessment (eCOA) trials.

The contract is worth over US$750,000 with a new client for the Company, a specialty pharmaceutical developer, over a one-year period. It is the largest of a number of eCOA contracts won since Cambridge Cognition decided to increase the value of its software service by expanding the capabilities of its CANTAB Connect platform. The technology now enables the assessment of multiple outcomes, in addition to cognitive measures, on a single platform.

This latest contract is for a phase IV trial which will use the Company's robust eCOA technology to evaluate treatment safety and tolerability with objective computerised cognitive assessments and additional clinician-reported outcome measures delivered to patients on touchscreen devices.

Performing multiple outcome assessments on the validated CANTAB Connect platform integrates data collection, reduces administrative burden and saves costs for study sites while improving data quality throughout the trial.

Dr Steven Powell, Chief Executive Officer, Cambridge Cognition said: "We are pleased to welcome another pharmaceutical partner to the growing number who trust our neuroscience technologies with the collection and analysis of valuable patient data. In 2018 we took the strategic decision, based on customer input, to enable clients to mitigate risks and reduce operational costs by measuring more outcomes on our proven CANTAB Connect platform. This series of recent contract wins further validates the Company's strategy and demonstrates our ability to translate customer requirements into revenue rapidly."

Enquiries

 
 Cambridge Cognition Holdings PLC 
  Steven Powell, Chief Executive Officer         Tel: 01223 810 700 
  Noah Konig, Director of Marketing              press@camcog.com 
 finnCap Ltd (NOMAD and Joint Broker)          Tel: 020 7220 0500 
  Geoff Nash / Simon Hicks                      (Corporate Finance) 
  Alice Lane                                    (Corporate Broking) 
 Dowgate Capital Stockbrokers Limited (Joint   Tel: 020 3903 7715 
  Broker) 
  David Poutney / James Serjeant 
 IFC Advisory Ltd (Financial PR and IR)        Tel: 020 3934 6630 
  Graham Herring / Miles Nolan / Zach Cohen

About Cambridge Cognition

Cambridge Cognition is a neuroscience technology company developing digital health products to better understand, detect and treat conditions affecting brain health. The company's software products assess cognitive health in patients worldwide to improve clinical trial outcomes, identify and stratify patients early, and reduce global R&D and healthcare costs.

For further information visit www.cambridgecognition.com

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

END

CNTFFIFMDFASEDF

(END) Dow Jones Newswires

November 14, 2018 02:00 ET (07:00 GMT)

Cambridge Cognition (LSE:COG)
Historical Stock Chart
From Apr 2024 to May 2024 Click Here for more Cambridge Cognition Charts.
Cambridge Cognition (LSE:COG)
Historical Stock Chart
From May 2023 to May 2024 Click Here for more Cambridge Cognition Charts.